Author:
Gupta Vikas,Ye Gang,Olesky Melanie,Lawrence Kenneth,Murray John,Yu Kalvin
Funder
Tetraphase Pharmaceuticals
Becton, Dickinson and Company
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. 2013.
https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
. Accessed 6 Aug 2018.
2. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discover, and development of new antibiotics. 2017.
http://apps.who.int/medicinedocs/documents/s23171en/s23171en.pdf
. Accessed 6 Aug 2018.
3. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.
4. Zalacain M, Biedenbach DJ, Badal RE, Young K, Motyl M, Sahm DE. Pathogen prevalence and antimicrobial susceptibility among Enterobacteriaceae causing hospital-associated intra-abdominal infections in adults in the United States (2012-2013). Clin Ther. 2016;38:1510–21.
5. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017;17:279.
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献